SG52589A1 - Antigenic epitopes presend on membrane-bound but not secreted iga - Google Patents

Antigenic epitopes presend on membrane-bound but not secreted iga

Info

Publication number
SG52589A1
SG52589A1 SG1996006485A SG1996006485A SG52589A1 SG 52589 A1 SG52589 A1 SG 52589A1 SG 1996006485 A SG1996006485 A SG 1996006485A SG 1996006485 A SG1996006485 A SG 1996006485A SG 52589 A1 SG52589 A1 SG 52589A1
Authority
SG
Singapore
Prior art keywords
bound
membrane
presend
secreted iga
antigenic epitopes
Prior art date
Application number
SG1996006485A
Other languages
English (en)
Inventor
Tse Wen Chang
Nancy T Chang
Original Assignee
Tanox Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/369,479 external-priority patent/US5079344A/en
Application filed by Tanox Biosystems Inc filed Critical Tanox Biosystems Inc
Publication of SG52589A1 publication Critical patent/SG52589A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG1996006485A 1989-06-21 1990-06-21 Antigenic epitopes presend on membrane-bound but not secreted iga SG52589A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/369,479 US5079344A (en) 1989-06-21 1989-06-21 Antigenic epitopes present on membrane-bound but not secreted IgA
US07/455,080 US5089603A (en) 1989-06-21 1989-12-22 Antigenic epitopes present on membrane-bound but not secreted iga

Publications (1)

Publication Number Publication Date
SG52589A1 true SG52589A1 (en) 1998-09-28

Family

ID=27004597

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996006485A SG52589A1 (en) 1989-06-21 1990-06-21 Antigenic epitopes presend on membrane-bound but not secreted iga

Country Status (11)

Country Link
US (2) US5089603A (fr)
EP (1) EP0478665B1 (fr)
JP (1) JP2612512B2 (fr)
AT (1) ATE189856T1 (fr)
AU (1) AU645256B2 (fr)
CA (1) CA2060666C (fr)
DE (1) DE69033461T2 (fr)
DK (1) DK0478665T3 (fr)
ES (1) ES2142790T3 (fr)
SG (1) SG52589A1 (fr)
WO (1) WO1990015614A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362643A (en) * 1989-06-21 1994-11-08 Tanox Biosystems Antibodies to epitopes present on membrane-bound but not secreted IGA
US5514776A (en) * 1987-12-31 1996-05-07 Tanox Biosystems, Inc. Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface
US5266477A (en) * 1990-02-02 1993-11-30 Pitman-Moore, Inc. Monoclonal antibodies which differentiate between native and modified porcine somatotropins
US20100267023A1 (en) * 1992-09-24 2010-10-21 Keygene N.V. Selective restriction fragment amplification: fingerprinting
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
IT1315254B1 (it) * 1999-11-05 2003-02-03 Diesse Diagnostica Senese Spa Metodo per la determinazione qualitativa e quantitativa di anticorpiumani di classe igc.
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
HUE026000T2 (en) * 2003-12-17 2016-04-28 Wyeth Llc Immunogenic peptide-bearing conjugates and methods for their preparation
SG182189A1 (en) * 2003-12-17 2012-07-30 Elan Pharma Int Ltd A(beta) immunogenic peptide carrier conjugates and methods of producing same
CA2590337C (fr) * 2004-12-15 2017-07-11 Neuralab Limited Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
WO2006066171A1 (fr) * 2004-12-15 2006-06-22 Neuralab Limited Anticorps amyloide ???? utilises afin d'ameliorer la cognition
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
CA2624081C (fr) 2005-09-29 2014-09-16 Medimmune, Inc. Methode d'identification d'anticorps specifiques de membranes et leurs utilisations pour cibler les precurseurs producteurs d'immunoglobuline
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008116149A2 (fr) * 2007-03-22 2008-09-25 Genentech, Inc. Anticorps anti-ige apoptopiques
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
MX2009011127A (es) * 2007-04-18 2010-03-10 Janssen Alzheimer Immunotherap Metodo de prevencion y tratamiento de angiopatia amiloide cerebral.
US20080283557A1 (en) * 2007-05-17 2008-11-20 Julianne Desautels Spout for food stuff container
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
HUE036920T2 (hu) 2009-02-25 2018-08-28 Academia Sinica Anti-C[epszilon]mX-ellenanyagok, amelyek képesek B-limfocitákon humán mlgE-hez kötõdni
EP2838919A4 (fr) 2012-04-20 2016-03-23 Academia Sinica Anticorps anti-mige (ige liées à la membrane) qui se lient à la jonction entre les domaines ch4 et c epsilon mx
CN106029092B (zh) * 2013-12-05 2019-11-19 中央研究院 能够溶解带有膜锚定型免疫球蛋白a的b淋巴球与降低免疫球蛋白a生产的抗人类膜锚定型免疫球蛋白a抗体
CA3079992A1 (fr) 2017-10-31 2019-05-09 Oneness Biotech Co. Ltd. Traitement de maladies allergiques mediees par ige

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE230883C (fr) *
US4636463A (en) * 1984-04-05 1987-01-13 Scripps Clinic And Research Foundation Antibodies to human interleukin-2 induced by synthetic polypeptides
EP0407392B2 (fr) * 1987-12-31 1998-10-28 Tanox Biosystems, Inc. Epitopes antigeniques uniques sur des lymphocytes b porteurs d'immunoglobuline e

Also Published As

Publication number Publication date
ES2142790T3 (es) 2000-05-01
DE69033461T2 (de) 2000-10-12
JP2612512B2 (ja) 1997-05-21
EP0478665A1 (fr) 1992-04-08
US5866129A (en) 1999-02-02
AU5854790A (en) 1991-01-08
EP0478665A4 (en) 1993-02-17
ATE189856T1 (de) 2000-03-15
CA2060666A1 (fr) 1990-12-22
CA2060666C (fr) 2001-07-10
AU645256B2 (en) 1994-01-13
DK0478665T3 (da) 2000-07-24
US5089603A (en) 1992-02-18
WO1990015614A1 (fr) 1990-12-27
EP0478665B1 (fr) 2000-02-23
JPH04504424A (ja) 1992-08-06
DE69033461D1 (de) 2000-03-30

Similar Documents

Publication Publication Date Title
EP0478665A4 (en) Antigenic epitopes present on membrane-bound but not secreted iga
ES515241A0 (es) Un metodo para la produccion de un polipeptido.
IT8319234A0 (it) Procedimento per la produzione di anticorpi monoclonali umani.
ZA919299B (en) Method for the production of antibodies
NO980293L (no) Fremgangsmåte til fremstilling av et polypeptid
DE3586697D1 (en) Aktive thymopentin-analoga.
NO881151D0 (no) Syntetisk hiv-1-antigen.
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
NL190877C (nl) Werkwijze voor de produktie van N#2-gas onder een super-atmosferische druk.
NL189208C (nl) Expressievector; werkwijze voor het bereiden daarvan; werkwijze voor het produceren van een polypeptide onder toepassing van genoemde expressievector.
IT8722011A0 (it) Procedimento per relaizzare un tessuto composito adatto per la fabbricazione di indumenti.
DE3260757D1 (en) Process for producing cement, and cement obtained by the process
DE3482813D1 (de) Adult t-zell-leukemiavirus-antigenpeptid.
NL173741C (nl) Werkwijze voor de vergroting van de druksterkte van cementmengsels.
DE3780256D1 (de) Anti-pci-monoklonaler antikoerper.
ATE207935T1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
NO904858D0 (no) Fremgangsmaate til rask mottagersynkronisering under utnyttelse av enfeilkorrigerende koding.
ES2061664T3 (es) Anticuerpos monoclonales que reconocen a alfa-hanp y correspondientes hibridomas, su preparacion y uso.
AR242832A1 (es) Polidomas productores de anticuerpos monoclonales hibridos biespecificos contra la fibrina y uk y/o pro uk y metodo para producirlos.
ES501321A0 (es) Un metodo de preparacion de un peptido inhibidor de la liberacion de gonadotropinas por la glandula pituitaria en mamiferos.
NO873488D0 (no) Monoklonale antistoffer.
MX9203574A (es) Metodo biotecnologico para la produccion de peptidos antigenicos relacionados con el antigeno p asociado al melanoma, y para preparar vacunas que los contienen.
NO894555L (no) Monoklonalt antistoff som spesifikt gjenkjenner n-glycolyl type gm2, hybridom som produserer antistoff og fremgangsmaate for fremstilling av hybridomet.
NZ223624A (en) Peptide immunogen from streptococcus mutans, vaccines and antibodies
EP0446763A3 (en) Antigen for producing anti-idiotype antibody, anti-idiotype antibody and method for producing the anti-idiotype antibody